A linear relationship between serum high-sensitive C-reactive protein and hemoglobin in hemodialysis patients

Clinical and Experimental Nephrology

Volumn 19, Issue 4, 2015, Pages 725-731

  Heidari, Behzad ^a   Fazli, Muhammad Reza ^b   Misaeid, Muhammad Ali Ghazi ^a   Heidari, Parham ^c   Hakimi, Niloofar ^d   Zeraati, Abbas Ali ^b  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Avina Clinic   (Iran)

^d Imam Reza Clinic   (Iran)

Author keywords

Anemia; Hemodialysis; Inflammation; Relationship; Serum C reactive protein

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CHOLESTEROL; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN; BIOLOGICAL MARKER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; C REACTIVE PROTEIN TEST KIT; DIAGNOSTIC TEST ACCURACY STUDY; END STAGE RENAL DISEASE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOTURBIDIMETRY; INFLAMMATION; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; LINEAR REGRESSION ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MIDDLE AGED; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; TREATMENT DURATION; TURBIDIMETRY; BLOOD; COMPLICATION; CROSS-SECTIONAL STUDY; DIABETES COMPLICATIONS; FEMALE; KIDNEY FAILURE, CHRONIC; MALE; METABOLISM; RENAL REPLACEMENT THERAPY;

ADULT; AGED; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; FEMALE; HEMOGLOBINS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84940438803     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-014-1048-0     Document Type: Article

References (42)

1. Heidari B. C-reactive protein and other markers of inflammation in hemodialysis patients. Caspian J Intern Med. 2013;4(1):611–6.
2. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998;54:627–36.
3. Collado S. Anemia in chronic kidney disease and its cardiovascular implications. Med Clin. 2009;132:38–42. doi:10.1016/S0025.
4. Yeun JY, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–76.
5. Chawla LS, Krishnan M. Causes and consequences of inflammation on anemia management in hemodialysis patients. Hemodial Int. 2009;13:222–34. doi:10.1111/j.1542-4758.2009.00352.x.
6. Al Saran K, Sabry A, Al Sherbeiny S, Abdelkader M. Level of C-reactive protein in chronic hemodialysis patients: a comparative study between patients with non-infected catheters and arteriovenous fistula in a large Saudi hemodialysis center. Ther Apher Dial. 2013;17:35–9.
7. Hung A, Pupim L, Yu C, et al. Determinants of C-reactive protein in chronic hemodialysis patients: relevance of dialysis catheter utilization. Hemodial Int. 2008;12:236–43. doi:10.1111/j.1542-4758.2008.00260.x.
8. Kaygin MA, Halici U, Aydin A, Dag O, Binici DN, Limandal HK, et al. The relationship between arteriovenous fistula success and inflammation. Ren Fail. 2013;35:1085-8. doi:10.3109/0886022X.2013.815100.
9. Kadiroglu AK, Kadiroglu ET, Sit D, Dag A, Yilmaz ME. Periodontitis is an important and occult source of inflammation in hemodialysis patients. Blood Purif. 2006;24(4):400–4.
10. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol. 2001;72(9):1221–7.
11. Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular risk extended evaluation in dialysis patients. J Hypertens. 2000;18(9):1207–13.
12. Madore F, Lowrie EG, Brugnara C, et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol. 1997;8(12):1921–9.
13. Panichi V, Rosati A, Bigazzi R, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transpl. 2011;26:2641–8. doi:10.1093/ndt/gfq802.
14. Mukhopadhyay P, Sinha U, Banerjee J, Choudhury AR, Philips CA. The effects in correction of anaemia in chronic kidney disease with erythropoietin therapy–preference to cardiovascular, neurologic and general well-being of patients from a tertiary care centre. J Indian Med Assoc. 2012;110(12):885–8.
15. Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transpl. 2003;18:17–22.
16. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol. 2000;20:345–9.
17. Stojceva-Taneva O, et al. Inflammation and anaemia as predictors of cardiovascular mortality in hemodialysis patients. Hippokratia. 2007;11:39–43.
18. Selim G, Stojceva-Taneva O, Sikole A, et al. Association between haemoglobin level and all-cause mortality in haemodialysis patients: the link with inflammation and malnutrition. Prilozi. 2007;28:81–95.
19. Lee CT, Lee CH, Su Y, Chuang YC, Tsai TL, Cheni JB. The relationship between inflammatory markers, leptin, adiponectin in chronic hemodialysis patients. Int J Artif Organs. 2004;27:833–41.
20. Panichi V, Migliori M, De Pietro S, et al. Plasma C-reactive protein in hemodialysis patients: a cross-sectional, longitu dinal clinical survey. Blood Purif. 2000;18:30–6.
21. Panichi V, Migliori M, De Pietro S, et al. C reactive protein in patients with chronic renal diseases. Ren Fail. 2001;23:551–62.
22. Lee CT, Lam KK, Lin CR, Chen JB. Inflammatory markers and hepatocyte growth factor in sustained hemodialysis hypotension. Artif Organs. 2005;29:980–3.
23. Firouzjahi A, Monadi M, Karimpoor F, Heidari B, Dankoob Y, Hajian-Tilaki K, Firozjahi MG. Serum C-reactive protein level and distribution in chronic obstructive pulmonary disease versus healthy controls: a case-control study from Iran. Inflammation. 2013;36:1122–8. doi:10.1007/s10753-013-9646-7.
24. Heidari B, Heidari P, Tayebi ME. The value of changes in CRP and ESR for predicting treatment response in rheumatoid arthritis. APLAR Journal of Rheumatology. 2007;10:23–8.
25. Bran P. Inflammation and, serum C-reactive protein and erythropoietin resistance. Nephrol Dial Transpl. 2001;16:224–7.
26. Rattanasompattikul M, Molnar MZ, Zaritsky JJ, et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transpl. 2013;28:1936–45. doi:10.1093/ndt/gfs368.
27. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis. Am J Kidney Dis. 1999;3:63–72.
28. Barany P, Filho JD, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997; 565–568.
29. Teruel JL, Marcen R, Ocaña J, et al. Clinical significance of C-reactive protein in patients on hemodialysis: a longitudinal study. Nephron Clin Pract. 2005;100:140–5.
30. Wang AY, Woo J, Lam CW, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol. 2003;14:871–9.
31. Chonchol M, Lippi G, Montagnana M, Muggeo M, Targher G. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrol Dial Transpl. 2008;23:2879–83. doi:10.1093/ndt/gfn109.
32. Iseki K, Kohagura K. Anemia as a risk factor for chronic kidney disease. Kidney Int Suppl. 2007;107:S4–9.
33. Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm. 2007; 64(13 Suppl 8): S3–7; quiz S23-5.
34. Kalantar-Zadeh K, Höffken B, Wünsch H, Fink H, Kleiner M, Luft FC. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis. 1995;26:292–9.
35. Makhlough A, Kosaryan M, Roshan P.Credibility of the measurement of serum ferritin and transferrin receptor as indicators of iron deficiency anemia in hemodialysis patients. Eur Rev Med Pharmacol Sci. 2011; 15: 1158–62.
36. Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transpl. 2003; 18(Suppl 8): viii17-22.
37. Valenti L, Messa P, Plusi S, Capostrinei N, Girelli D. Hepcidin levels in chronic hemodialysis patients: a critical evaluation. Clin Chem Lab Med. 2013; 14: 1–7.
38. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transpl. 2004; 19(91): 141–9.
39. Gonçalves SM, Dal Lago EA, de Moraes TP, et al. Lack of adequate predialyis care and previous hemodialysis, but not hemoglobin variability, are independent predictors of anemia-associated mortality in incident Brazilian peritoneal dialysis patients: results from the BRAZPD study. Blood Purif. 2012;34:298–305. doi:10.1159/000342618.
40. Brattich M. Relationships between hemoglobin and hematocrit levels and hospitalization and survival rates in dialysis patients. Nephrol Nurs J. 2003;30:231–4.
41. Snaedal S, Heimbürger O, Qureshi AR, et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis. 2009;53:1024–33. doi:10.1053/j.ajkd.2009.02.008.
42. Siribamrungwong M, Puangpanngam K. Treatment of periodontal diseases reduces chronic systemic inflammation in maintenance hemodialysis patients. Ren Fail. 2012;34:171–5. doi:10.3109/0886022X.2011.643351.